Summary
Emcure Pharmaceuticals has received CDSCO approval to market its brand Poviztra for the treatment of fatty liver (metabolic dysfunction-associated steatohepatitis) in adults. Poviztra contains semaglutide manufactured by Novo Nordisk, expanding treatment access for patients with this condition.